Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma

Authors

  • Michael Clarke,

    1. Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA,
    2. University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Search for more papers by this author
  • Bernhard Ortel,

    1. Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA,
    2. University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Search for more papers by this author
  • Bruce Brockstein,

    1. Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA,
    2. University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Search for more papers by this author
  • Theera Rojanapremsuk,

    1. Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA,
    2. University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Search for more papers by this author
  • Thomas Victor,

    Corresponding author
    1. University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    • Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA,
    Search for more papers by this author
  • Antoinette Thomas,

    1. Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA,
    2. University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Search for more papers by this author
  • Thomas Cibull

    1. Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA,
    2. University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Search for more papers by this author

Thomas Cibull, MD,

Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA

Tel: 847 570 4024

Fax: 847 570 2809

e-mail: tcibull@northshore.org

Abstract

BRAF inhibition therapy, used to treat melanomas with BRAF mutations, is associated with both neoplastic and non-neoplastic cutaneous side effects including squamous cell carcinomas, warty dyskeratomas, verrucous keratoses, photosensitivity and widespread eruptions that present histopathologically as acantholytic dyskeratosis. We report a case of a patient undergoing BRAF inhibition therapy for disseminated melanoma with a V600E mutation who developed bilateral areolar leiomyomas, one of which was biopsied and the other of which resolved after discontinuation of vemurafenib therapy. To our knowledge, this is the first reported case of a mesenchymal neoplasm developing in association with BRAF inhibition therapy.

Ancillary